



2nd NIH Mesothelioma Conference

March 6, 2009 • Lipsett Auditorium • National Institutes of Health • Bethesda, MD

- 8:45 – 8:55 **Welcome and Opening Remarks**
Raffit Hassan, MD, National Cancer Institute
- 8:55 – 9:00 **Introductory Comments**
Lee Helman, MD, Scientific Director, National Cancer Institute
- 9:00 – 9:30 **Opening Speaker**
Ira Pastan, MD, National Cancer Institute
Identification and characterization of mesothelin as target for cancer therapy
- 9:30 – 10:45 **Scientific Session I: Advances in mesothelioma biology**
Chair: **Michele Carbone, MD, PhD**, Cancer Research Center of Hawaii
Speakers: **Joseph Testa, PhD**, Fox Chase Cancer Center
Molecular pathways in malignant mesothelioma pathogenesis: Lessons from human cell lines and mouse models
V. Courtney Broaddus, MD, University of California, San Francisco
The role of the mitochondria in acquired 3D apoptotic resistance in mesothelioma
Prasad Adusumilli, MD, Memorial Sloan-Kettering Cancer Center
Targeting T cells to mesothelin in pleural mesothelioma animal models
- 10:45 – 11:00 *Refreshment Break*
- 11:00 – 12:15 **Scientific Session II: Novel approaches for mesothelioma therapy**
Chair: **Giuseppe Giaccone, MD, PhD**, National Cancer Institute
Speakers: **David Sugarbaker, MD**, Brigham and Women's Hospital
Advances in the multimodality therapy of mesothelioma
Lee Krug, MD, Memorial-Sloan Kettering Cancer Center
Optimizing combined modality approaches for MPM
Robert Taub, MD, PhD, The University Hospitals of Columbia and Cornell
Intracavitary chemotherapy for abdominal and pleural mesothelioma
- 12:15 – 1:15 *Lunch (on own)*
- 1:15 – 2:50 **Scientific Session III: Chemotherapy for treatment of malignant mesothelioma**
Chair: **Julie Brahmer, MD**, Johns Hopkins University
Claudio Dansky Ullmann, MD, National Cancer Institute

(See reverse for more afternoon sessions)



2nd NIH Mesothelioma Conference

Speakers: **Nicholas Vogelzang, MD**, Nevada Cancer Institute

After pemetrexed and cisplatin, what is the way forward?

Anna Nowak, PhD, The University of Western Australia

Clinical trials of novel agents and novel uses for old agents in malignant mesothelioma: current clinical trials from the Perth Mesothelioma Centre

Karim Vermaelen, MD, PhD, Ghent University, Belgium

Value and pitfalls of SMP as a biomarker in MPM: a Belgian multicenter study design

Michele Carbone, MD, PhD, Cancer Research Center of Hawaii

Results of a randomized Phase 3 clinical trial using Onconase+doxorubicin versus doxorubicin alone and possible use of Onconase in individuals from high risk families with high levels of mesothelin/osteopontin

2:50 – 3:05

Refreshment Break

3:05 – 4:20

Scientific Session IV: Pre-clinical and clinical trials of immunotherapy in mesothelioma

Chair: **Jeff Schlom, PhD**, National Cancer Institute

Mitchell Ho, PhD, National Cancer Institute

Speakers: **Steven Albelda, MD**, University of Pennsylvania Medical Center

Immunogene therapy for mesothelioma: successes and challenges

Brooke Mossman, PhD, University of Vermont

Microparticles for release of chemotherapeutic drugs and siconstructs in therapy of mesotheliomas

Raffit Hassan, MD, National Cancer Institute

Mesothelin targeted chemo-immunotherapy for mesothelioma

4:20 – 5:35

Scientific Session V: Mesothelioma as a global health problem

Chair: **Shiekh Aejaz Aziz, MD**, Sher-i-Kashmir Institute of Medical Sciences, India

Raffit Hassan, MD, National Cancer Institute

Speakers: **Brad Black, MD**, Center for Asbestos Related Disease, Libby, MT

Libby amphibole asbestos: Progressive pleural fibrosis and mesothelioma

Jeremy Steele, MD, London Oncology Clinic - Barts and The London Cancer Centre

The implications of mesothelioma epidemiological trends in the UK and Europe

Vinod Raina, MD, All India Institute of Medical Sciences, India

Mesothelioma in India and challenges in a fast industrialising country

